Programs
Reference programs across the drug-development lifecycle, the offerings stack, customer segments, and the value-chain map.
We sell in two modes: platform subscriptions (LabOS, OmicsCloud, Atlas licensing) and milestone-gated discovery sprints (IVD CDx, pharma lifecycle programs, Phase 4 PV). Reference programs prove the sprint model; offerings define the full product catalog.
Track A · Reference Programs
Flagship sprints with full costed timelines — IVD Companion Diagnostics (18 mo / $5M) and the pharma R&D lifecycle (target discovery through pharmacovigilance).
Track B · Commercial Stack
LabOS platform, OmicsCloud, India Biomarker Atlas licensing, ClinicalBridge packages, and co-development partnerships.
Two flagship sprints
IVD CDx — 18 months, $5M, oncology companion diagnostic on Apollo cohorts. Phase 4 PV — $2.5M/yr recurring, India PGx signal detection. Both anchor on Apollo data and LabOS orchestration. Read case studies →
Reference Programs →
IVD Companion Diagnostics + the full Pharma R&D lifecycle.
Offerings & USP →
LabOS as flagship plus five differentiated USPs.
India Biomarker Atlas →
Proprietary biomarker database on Apollo substrate — licensable asset.
Customer Segments →
Six buyer personas with distinct pains and segment-specific value.
Value Chain Map →
Where we intervene across target ID through pharmacovigilance.
Case Studies →
Hypothetical end-to-end programs for generic pharma and MNC APAC.